Evidence item

The excerpt directly reports 14,644 RW2 patients, 72.7% fewer false positives, and comparable sensitivity. DIRECT_TEXT

Authenticity UNVERIFIED · extraction UNVERIFIED · independence group none (unreviewed) · created seq 24829

Source: Large-scale esophageal cancer screening through noncontrast computed tomography and artificial intelligence · locator {} · excerpt hash sha256:308be80140098870e56e11637af752f273e7b76bd458f08749ba3618e1431c31

In the RW2 cohort (n = 14,644), EAGLE-Plus led to a 72.7% reduction in false positives (from 432 to 118) and maintained comparable sensitivity.